---
title: "Sokal score"
slug: "sokal-score"
date: "2023-06-07"
enableToc: false
tags:
- building
---

> [!info]
>
> 🌱 來自: [[prognosis of chronic myelogenous leukemia (CML)]]

# Sokal score

* categories:
	* low vs. intermediate vs. high
* calculated from % peripheral blasts, plt count, spleen size, age)
(Blood 1984;63:789)

一個老人、在在喝啤酒、玩血小板、然後就爆了

| Parameter                         | Norm        |
|-----------------------------------|-------------|
| Age                               | 0 - 0 years |
| Spleen size                       | 0 - 12.7cm  |
| Platelet count                    | 150k        |
| % myeloblasts in peripheral blood | 0 - 0%      |

---

| Risk Group   | Sokal Score | 2-year Survival | Median Survival |
|--------------|-------------|-----------------|-----------------|
| Low          | <0.8        | 90%             | 5 years         |
| Intermediate | 0.8–1.2     | 65-90%          | 2.5-5 years     |
| High         | >1.2        | 65%             | 2.5 years       |

## 美國是否採用EUTOS評分來評估CML患者風險和指導治療？

- 摘要：在美國，雖然[[EUTOS]]評分在慢性粒線白血病（CML）的酪氨酸激酶抑制劑時代更容易計算並更準確地識別高風險患者，但尚未被美國國家綜合癌症網絡（NCCN）指南所採納。相反，NCCN指南使用Sokal評分來評估CML患者的風險並指導治療。

- 原文：In the United States, the EUTOS score, despite being easier to calculate and more accurate in identifying high-risk patients in the era of tyrosine kinase inhibitors, has not been adopted by the National Comprehensive Cancer Network (NCCN) guidelines. Instead, the NCCN guidelines utilize the Sokal Score to assess the risk and guide therapy decisions for chronic myeloid leukemia (CML).
